Allianz Asset Management
APLS

Allianz Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Allianz Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,000
Closed -$427K – 2003
2025
Q4 		$427K Hold
17,000
– – ﹤0.01% 1854
2025
Q3 		$385K Buy
+17,000
New +$396K ﹤0.01% 1895
2025
Q2 		– Sell
-18,800
Closed -$411K – 2002
2025
Q1 		$411K Hold
18,800
– – ﹤0.01% 1941
2024
Q4 		$600K Buy
18,800
+11,400
+154% +$343K ﹤0.01% 1800
2024
Q3 		$213K Sell
7,400
-6,200
-46% -$230K ﹤0.01% 2070
2024
Q2 		$522K Hold
13,600
– – ﹤0.01% 1822
2024
Q1 		$799K Hold
13,600
– – ﹤0.01% 1487
2023
Q4 		$814K Hold
13,600
– – ﹤0.01% 1685
2023
Q3 		$517K Sell
13,600
-9,000
-40% -$395K ﹤0.01% 1912
2023
Q2 		$2.06M Buy
22,600
+4,600
+26% +$397K ﹤0.01% 1267
2023
Q1 		$1.19M Buy
+18,000
New +$1.04M ﹤0.01% 1619
2022
Q4 		– Sell
-11,000
Closed -$751K – 1976
2022
Q3 		$751K Sell
11,000
-44,140
-80% -$2.61M ﹤0.01% 1465
2022
Q2 		$2.49M Buy
55,140
+22,590
+69% +$1.03M ﹤0.01% 1347
2022
Q1 		$1.65M Buy
32,550
+3,200
+11% +$141K ﹤0.01% 1661
2021
Q4 		$1.39M Buy
+29,350
New +$1.16M ﹤0.01% 1763
2021
Q3 		– Sell
-26,240
Closed -$1.66M – 2535
2021
Q2 		$1.66M Buy
26,240
+20,940
+395% +$1.08M ﹤0.01% 1536
2021
Q1 		$227K Hold
5,300
– – ﹤0.01% 2101
2020
Q4 		$303K Sell
5,300
-18,820
-78% -$796K ﹤0.01% 1741
2020
Q3 		$728K Sell
24,120
-2,102
-8% -$62.8K ﹤0.01% 1517
2020
Q2 		$857K Sell
26,222
-1,900
-7% -$61K ﹤0.01% 1871
2020
Q1 		$753K Sell
28,122
-2,482
-8% -$88.1K ﹤0.01% 1901
2019
Q4 		$937K Buy
+30,604
New +$847K ﹤0.01% 2229

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Allianz Asset Management's APLS Position: Q1 2026 in Review

Allianz Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 17,000 shares — an estimated $427K sold.

Allianz Asset Management first reported a position in APLS in Q4 2019 and held it in 22 quarters. The position peaked at $2.49M in Q2 2022. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Allianz Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Allianz Asset Management sold 17,000 Apellis Pharmaceuticals shares in Q1 2026, an estimated $427K.
  • Allianz Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 22 quarters.
  • Allianz Asset Management's Apellis Pharmaceuticals position peaked at $2.49M in Q2 2022.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.